Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
625.02B
Market cap625.02B
Price-Earnings ratio
29.71
Price-Earnings ratio29.71
Dividend yield
2.04%
Dividend yield2.04%
Average volume
8.07M
Average volume8.07M
High today
$254.48
High today$254.48
Low today
$250.51
Low today$250.51
Open price
$254.48
Open price$254.48
Volume
2.81M
Volume2.81M
52 Week high
$274.90
52 Week high$274.90
52 Week low
$166.64
52 Week low$166.64

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $253.55, with a market capitalization of 625.02B. The stock trades at a price-to-earnings (P/E) ratio of 29.71 and offers a dividend yield of 2.04%.

On 2026-08-04, Johnson & Johnson(JNJ) stock moved within a range of $250.51 to $254.48. With shares now at $253.55, the stock is trading +1.2% above its intraday low and -0.4% below the session's peak.

Trading volume for Johnson & Johnson(JNJ) stock has reached 2.81M, versus its average volume of 8.07M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $274.90 and a low of $166.64.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $274.90 and a low of $166.64.

JNJ News

TipRanks 1h
JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Analyst Asad Haider of Goldman Sachs reiterated a Buy rating on Johnson & Johnson, retaining the price target of $282.00. Claim 55% Off TipRanks Unlock powerful...

TipRanks 2h
Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Johnson & Johnson, retaining the price target of $294.00. Unlock powerful investing tools wi...

TipRanks 3h
Johnson & Johnson announces leadership change in Innovative Medicine

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
23.1%
Sell
3.8%

More JNJ News

TipRanks 4h
Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Johnson & Johnson announced that Jennifer Taubert will retire from her position as Executive Vice President, EVP, Worldwide Chairman, Innovative Medicine. Taube...

TipRanks 12h
Analyst Reiterates Buy on Intuitive Surgical, Seeing Johnson & Johnson’s Ottava as a Growth Catalyst Rather Than a Competitive Threat

TD Cowen analyst Mathew Blackman maintained a Buy rating on Intuitive Surgical yesterday and set a price target of $485.00. Unlock powerful investing tools wit...

New York Times 20h
Bills camp notes: Options in C.J. Gardner-Johnson’s absence, unheralded eye-catchers - The New York Times

...

Bills camp notes: Options in C.J. Gardner-Johnson’s absence, unheralded eye-catchers - The New York Times
TipRanks 1d
Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

Wells Fargo raised the firm’s price target on Johnson & Johnson to $282 from $272 and keeps an Overweight rating on the shares. The firm is lower its EPS estima...

Simply Wall St 3d
Johnson & Johnson Makes Three Big Oncology Moves In A Week

Johnson & Johnson (NYSE:JNJ) has completed its acquisition of Firefly Bio, adding a degrader antibody therapy platform to its oncology toolkit. The company has...

Johnson & Johnson Makes Three Big Oncology Moves In A Week
The Motley Fool 4d
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Abbott Laboratories (ABT +0.42%) and Johnson & Johnson (JNJ +0.65%) involves weighing steady growth against massive scale. Both healthcare gian...

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 5d
Contineum reports Q2 EPS (40c), consensus (45c)

Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026. Contineum (CTNM) believes its cash resources are sufficient to fund it...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.